-
公开(公告)号：BR112021015238A8
公开(公告)日：2022-08-16
申请号：BR112021015238
申请日：2020-01-30
Applicant: LAVA THERAPEUTICS B V , LAVA THERAPEUTICS N V
Inventor： JOHANNES JELLE VAN DER VLIET , IRIS DE WEERDT , TANJA DENISE DE GRUIJL , PAUL PARREN , ARON PHILIP KATER , GEORGE LODEWIJK SCHEFFER
Abstract: NOVOS ANTICORPOS DE LIGAÇÃO A CD40. A presente invenção se refere a novos anticorpos capazes de se ligar a CD40 humano e a novos anticorpos multiespecíficos capazes de se ligar a CD40 humano e de se ligar a um receptor de células T V¿9V¿2 humano. A invenção também se refere a composições farmacêuticas que compreendem os anticorpos da invenção e aos usos dos anticorpos da invenção para tratamento médico.
-
公开(公告)号：AU2019344300A1
公开(公告)日：2021-04-22
申请号：AU2019344300
申请日：2019-09-19
Applicant: LAVA THERAPEUTICS N V
Inventor： VAN DER VLIET JOHANNES JELLE , LAMERIS ROELAND , DE GRUIJL TANJA DENISE , PARREN PAUL WILLEM HENRI IDA
IPC: C07K16/28 , A61K39/395 , A61P35/04
Abstract: The present invention relates to the field of immunology, more in particular to the field of binding moieties and/or immunoglobulins which bind to human CD1d, including antibodies and fragments thereof that modify CD1d-mediated biological functions such as enhanced activation and reduced activation of CD1d-restricted T cells, including the natural killer T- cells and gamma-delta T-cells, and modulation of the function of cells expressing CD1d. The invention also relates to bi-, tri-or multi-specific immunoglobulins that bind to CD1d and a gamma-delta TCR and/or a tumor target. The invention further relates to pharmaceutical preparations and use of such mono-, bi-,and tri-or multi-specific binding moieties and/or immunoglobulins in the treatment of diseases or disorders.
-
公开(公告)号：MX386714B
公开(公告)日：2025-03-11
申请号：MX2017009680
申请日：2017-07-26
Applicant: LAVA THERAPEUTICS N V
Inventor： VERHEUL HENDRIK MARINUS WILLEM , VAN DER VLIET JOHANNES JELLE , DE BRUIN RENÉE CORNELIA GERARDA , LAMERIS ROELAND , DE GRUIJL TANJA DENISE
Abstract: La presente invención se refiere a compuesto, en particular a polipéptidos que se unen específicamente a la proteína MHC no clásica CD1d y modulan las funciones biológicas mediadas por CD1d; la invención en particularmente relacionada a tales compuestos y polipéptidos que comprenden o consisten en al menos un anticuerpo de dominio simple se une específicamente a CD1d; también se proporcionan métodos y el uso empleando tales compuestos, polipéptidos y/o anticuerpos de dominio simple.
-
公开(公告)号：IL317337A
公开(公告)日：2025-01-01
申请号：IL31733724
申请日：2024-11-28
Applicant: LAVA THERAPEUTICS N V , PARREN PAUL WILLEM HENRI IDA , ROOVERS ROBERTUS CORNELIS , VAN DER VLIET JOHANNES JELLE , LUTJE HULSIK DAVID , MACHIELSEN PETER ALEXANDER GERARDUS MARIA , VAN WESTERHOVEN MICHIEL , KING LISA ANNA , FENNEMANN FELIX LENNART , MOUSSET CHARLOTTE MERETTE , ADANG ANTON EGBERT PETER
Inventor： PARREN PAUL WILLEM HENRI IDA , ROOVERS ROBERTUS CORNELIS , VAN DER VLIET JOHANNES JELLE , LUTJE HULSIK DAVID , MACHIELSEN PETER ALEXANDER GERARDUS MARIA , VAN WESTERHOVEN MICHIEL , KING LISA ANNA , FENNEMANN FELIX-LENNART , MOUSSET CHARLOTTE MERETTE , ADANG ANTON EGBERT PETER
IPC: A61K39/395 , A61P35/00 , C07K16/28 , C07K16/46
Abstract: The present invention relates to antibodies capable of binding a human Vγ9Vδ2 T cell receptor. The invention further relates to pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment.
-
公开(公告)号：BR112021005184A8
公开(公告)日：2022-08-16
申请号：BR112021005184
申请日：2019-09-19
Applicant: LAVA THERAPEUTICS B V , LAVA THERAPEUTICS N V
Inventor： JOHANNES JELLE VAN DER VLIET , ROELAND LAMERIS , TANJA DENISE DE GRUIJL , PAUL WILLEM HENRI IDA PARREN
IPC: C07K16/28 , A61K39/395 , A61P35/04
Abstract: IMUNOGLOBULINA CD1D DE DUPLA AÇÃO. A presente invenção se refere ao campo da imunologia, mais em particular ao campo das frações de ligação e/ou imunoglobulinas que se ligam a CD1d humano, incluindo anticorpos e fragmentos dos mesmos que modificam funções biológicas mediadas por CD1d, como ativação intensificada e ativação reduzida de células T restritas a CD1d, incluindo as células T exterminadoras naturais e células T gamadelta, e modulação da função de células que expressam Cd1d. A invenção também se refere a imunoglobulinas bi-, tri ou multiespecíficas que se ligam a CD1d e a um TCR gama-delta e/ou um alvo tumoral. A invenção refere-se adicionalmente a preparações farmacêuticas e uso de tais unidades de ligação mono-, bi-, e tri- ou multiespecíficas e/ou imunoglobulinas no tratamento de doenças ou distúrbios.
-
Patent Agency Ranking
公开(公告)号：AU2016212777B2
公开(公告)日：2021-11-18
申请号：AU2016212777
申请日：2016-01-27
Applicant: LAVA THERAPEUTICS N V
Inventor： VAN DER VLIET JOHANNES JELLE , DE GRUIJL TANJA DENISE , VERHEUL HENDRIK MARINUS WILLEM , DE BRUIN RENEE CORNELIA GERARDA , LAMERIS ROLAND
IPC: C07K16/28
Abstract: The invention relates to compounds, in particular polypeptides that specifically bind to the non-classical MHC protein CD1d and modulate CD1d-mediated biological functions. The invention in particular relates to such compounds and polypeptides comprising or consisting of at least one single domain antibody, and wherein at least one single domain antibody specifically binds to CD1d. Also provided is for methods and use employing such compounds, polypeptides and/or single-domain antibodies.
-
公开(公告)号：AU2020213325A1
公开(公告)日：2020-08-27
申请号：AU2020213325
申请日：2020-08-05
Applicant: LAVA THERAPEUTICS N V
Inventor： VAN DER VILET JOHANNES JELLE , DE BRUIN RENEE CORNELIA GERARDA , DE GRUILJ TANJA DENISE , VERHEUL HENDRIK MARINUS WILLEM
IPC: C07K16/28
Abstract: Abstract: The invention is in the field of medicine and relates to immunology, and relates in particular to human Vy9V62 T cell receptor binding immunoglobulin molecules. Human Vy9V62 T cell receptor binding immunoglobulin molecules are in particular for use in medical treatment and/or useful in assays with human Vy9V62 T cells, wherein human Vy9V62 T cells may be modulated.
-
公开(公告)号：MX385333B
公开(公告)日：2025-03-18
申请号：MX2016013332
申请日：2016-10-10
Applicant: LAVA THERAPEUTICS N V
Inventor： VERHEUL HENDRIK MARINUS WILLEM , VAN DER VLIET JOHANNES JELLE , DE BRUIN RENÉE CORNELIA GERARDA , DE GRUIJL TANJA DENISE
Abstract: La presente invención se refiere a está en el campo de la medicina y se refiere a la inmunología, y se refiere en particular a moléculas de inmunoglobulina que se unen al receptor de célula T V?9Vd2 humanas; las moléculas de inmunoglobulina que se unen al receptor de célula T V?9Vd2 humanas son en particular para su uso en el tratamiento médico y/o útiles en pruebas con células T V?9Vd2 humanas, en donde la células T V?9Vd2 humanas pueden ser moduladas.
-
公开(公告)号：AU2023293961A1
公开(公告)日：2024-12-19
申请号：AU2023293961
申请日：2023-06-15
Applicant: LAVA THERAPEUTICS N V
Inventor： PARREN PAUL WILLEM HENRI IDA , ROOVERS ROBERTUS CORNELIS , VAN DER VLIET JOHANNES JELLE , LUTJE HULSIK DAVID , MACHIELSEN PETER ALEXANDER GERARDUS MARIA , VAN WESTERHOVEN MICHIEL , KING LISA ANNA , FENNEMANN FELIX-LENNART , MOUSSET CHARLOTTE MERETTE , ADANG ANTON EGBERT
IPC: A61K39/395 , A61P35/00 , C07K16/28 , C07K16/46
Abstract: The present invention relates to antibodies capable of binding a human Vγ9Vδ2 T cell receptor. The invention further relates to pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment.
-
公开(公告)号：AU2023288542A1
公开(公告)日：2024-12-19
申请号：AU2023288542
申请日：2023-06-23
Applicant: LAVA THERAPEUTICS N V
Inventor： RIEDL THILO ALEXANDER , HOENDERDOS KIM , ADANG ANTON EGBERT PETER , VAN DER VLIET JOHANNES JELLE
IPC: G01N33/569 , C12N5/0783
Abstract: The present disclosure provides reporter T cells expressing a γδ T cell receptor (TCR) and a reporter gene, wherein the reporter gene is expressed when the T cell is activated. Also provided are assays that utilize the modified T cells to detect and/or quantitate T cell dependent binding compounds directed to a γδTCR and a target antigen and to determine the relative potency of such binding compounds.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.024 seconds)
